Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
ABLE LABS BANKRUPTCY

Able Laboratories files bankruptcy suit with US court

 

BY OUR PHARMA  CORRESPONDENT

 July 30, 2005: Able Laboratories filed a petition to reorganise under Chapter 11 of the US Bankruptcy Code in the US Bankruptcy Court for the District of New Jersey, Trenton Division on July 18, 2005.

The move has come after the company suspended manufacturing operations in May 2005, and recalled its product line after concerns were raised about laboratory practices and compliance with standard operating procedures.

The bankruptcy filing was intended to help it continue whilst it works with the FDA to get its operations back on line. In conjunction with the filing, Able also filed a number of 'first day motions'. These included requests to retain a Chief Restructuring Officer and a Director of Restructuring, as well as other professionals necessary to support the company's reorganization.

During the restructuring process, vendors, suppliers and other providers will be paid under normal terms for goods and services provided after the filing date, Able said in a press statement.

Able Laboratories, Inc. is a developer and manufacturer of generic pharmaceutical products in tablet,capsule, liquid and suppository dosage forms. In May 2005, Able suspended manufacturing and distribution of its entire product line. The company currently is not generating income or revenue, because of its suspension of manufacturing operations and product recalls.

 

MORE CORPORATE NEWS
Deals and pacts, mergers and acquisitions, lawsuits etc

Second trial on Merck’s painkiller Vioxx begins
17 September, 2005

Impax delisted from Nasdaq

39 drug firms sued over price rigging in California

Chiron rebuffs Novartis' bid

Nasdaq delists Able on bankruptcy filing

Some of the Vioxx suits may be settled: Merck

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

Ranbaxy acquires generic product portfolio from Efarmes

Novasite Pharma buys PsyCheNomicS

Temasek sets up $112 million pharma JV

Able Laboratories files bankruptcy suit with US court

Cardiac Science-Defibtech lawsuit settled

Par loses ondansetron case to GSK

Florida sues Mylan, Teva and Watson

Lupin in pact with Kyowa of Japan

British Pharma seeks opinion on industry code

European biotech start-ups fail to win late-stage funds

Afghan’s first generics plant to go on stream by Oct. ‘05

Merck sets up generic arm Genpharm in US

Novo Nordisk, Eli Lilly remove insulin products from Australia

Glaxo inks co-promotion pact with Eisai for Paritec

Elder Pharma plans unit, brand acquisition

Nectar Lifesciences plans Rs 90 crore IPO

Genepharm in pact with 3 Australian distributors 

Novartis acquires Bristol-Myers’ OTC business in US

Novartis completes Eon Labs buy

Orbus inks supply pact with Docpharma 

Novartis acquires rights of kidney dialysis drug from SeBo

Nektar buys out Aerogen for $32 m

BioVeris licenses Baxter's vaccine portfolio

Carl Icahn sells Mylan shares

Dey and Connecticut settle pricing dispute

   Pharma Home

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us